Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cerilliant
Cipla
Fuji
Citi
Federal Trade Commission
Moodys
UBS
Novartis
Fish and Richardson

Generated: October 24, 2017

DrugPatentWatch Database Preview

SODIUM THIOSULFATE Drug Profile

« Back to Dashboard

What is the patent landscape for Sodium Thiosulfate, and when can generic versions of Sodium Thiosulfate launch?

Sodium Thiosulfate is a drug marketed by Hope Pharms and Us Army and is included in two NDAs. There are three patents protecting this drug.

This drug has twelve patent family members in five countries and twenty-nine supplementary protection certificates in seven countries.

The generic ingredient in SODIUM THIOSULFATE is sodium thiosulfate. There are one thousand four hundred drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium thiosulfate profile page.

Summary for Tradename: SODIUM THIOSULFATE

US Patents:3
Applicants:2
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list50
Clinical Trials: see list2,406
Patent Applications: see list1,432
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SODIUM THIOSULFATE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hope Pharms
SODIUM THIOSULFATE
sodium thiosulfate
SOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Hope Pharms
SODIUM THIOSULFATE
sodium thiosulfate
SOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Hope Pharms
SODIUM THIOSULFATE
sodium thiosulfate
SOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Hope Pharms
SODIUM THIOSULFATE
sodium thiosulfate
SOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Us Army
SODIUM THIOSULFATE
sodium thiosulfate
INJECTABLE;INJECTION020166-001Feb 14, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SODIUM THIOSULFATE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,715,746Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,579,345Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,144,580Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SODIUM THIOSULFATE

Country Document Number Estimated Expiration
Japan2016153360► Subscribe
Japan5905387► Subscribe
Australia2010270605► Subscribe
World Intellectual Property Organization (WIPO)2011005841► Subscribe
European Patent Office2451435► Subscribe
Japan6166393► Subscribe
Japan2016106110► Subscribe
Canada2767168► Subscribe
Japan2017165758► Subscribe
Japan2012532824► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SODIUM THIOSULFATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
C0022France► SubscribePRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C0041France► SubscribePRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
C/GB98/025United Kingdom► SubscribePRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
90062-5Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
C/GB00/021United Kingdom► SubscribePRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Accenture
Cantor Fitzgerald
Boehringer Ingelheim
McKesson
Federal Trade Commission
Daiichi Sankyo
Dow
AstraZeneca
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot